New Methods And Guidelines For The Design, Analysis And Reporting Of Cluster-crossover And Stepped Wedge Randomised Trials In Clinical And Public Health Research
Funder
National Health and Medical Research Council
Funding Amount
$391,258.00
Summary
Cluster crossover and stepped wedge designs have emerged recently as study designs used in clinical and public health research settings. However, despite their use there has been very little methodological assessment of the statistical analysis methods used in current practice. The proposed research will assess the correctness of current methods and will produce a toolkit of state-of-the art, defensible trial design, analysis and reporting methods for the clinical/health researcher.
First Nations AI: Country, Climate, Communication. Our team of Indigenous and western scholars aims to develop a systematic account of artificial intelligence and its possibilities in climate change communication in remote First Nations communities in northern Australia. Working under Indigenous governance, we will establish spaces for Indigenous landowners and scientists to come together to probe diverse AI techniques for making sense of climate predictions and risks. We will build the capacity ....First Nations AI: Country, Climate, Communication. Our team of Indigenous and western scholars aims to develop a systematic account of artificial intelligence and its possibilities in climate change communication in remote First Nations communities in northern Australia. Working under Indigenous governance, we will establish spaces for Indigenous landowners and scientists to come together to probe diverse AI techniques for making sense of climate predictions and risks. We will build the capacity of Indigenous people to conceive and design AI, accounting for divergent languages and knowledge systems. This is expected to lead to more effective and trustworthy communications about extreme weather and climate change, improving the preparedness and responses of remote First Nations communities.Read moreRead less
Plasma Exchange And Glucocorticoids In ANCA Associated Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$635,243.00
Summary
Vasculitis is a life-threatening disease, and the current treatment for this condition is not satisfactory. This clinical trial aims to determine 1) if plasma exchange can lower mortality and the development of severe kidney failure due to this disease, and 2) if the use of lower doses of corticosteroids can lessen the infectious complications of treatment. This trial is part of a major international effort which will involve a total of 500 patients from Australia, UK, Europe, USA and NZ.
Large-scale Randomised Evidence: The Reliable Detection Or Refutation Of Treatment Effects Through Large, Simple Randomised Trials And Collaborative Meta-analyses Of Trials Using Individual Participant Data
Funder
National Health and Medical Research Council
Funding Amount
$425,897.00
Summary
Randomised controlled trials are the most reliable scientific method of studying medical treatments. Well-designed trials are thus needed to confidently guide doctors, other health professionals and policy-makers, particularly for common conditions such as cardiovascular disease. This Fellowship will study how we can better prevent and treat cardiovascular disease through the design, conduct and analysis of such trials at the University of Oxford, a world-leader in randomised controlled trials.
A Randomised Controlled Trial Of The Effect Of Hydrocortisone On Mortality In Critically Ill Patients With Septic Shock
Funder
National Health and Medical Research Council
Funding Amount
$3,432,452.00
Summary
This study performed across Australia and New Zealand will evaluate whether hydrocortisone, a cheap drug when administered to critically ill patients with severe infection, will save lives.
VITATOPS - A Randomised Controlled Trial Of Vitamins To Prevent Stroke
Funder
National Health and Medical Research Council
Funding Amount
$391,364.00
Summary
A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS ....A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS study arises from a large body of consistent, biologically plausible evidence linking homocysteine in a dose-dependent fashion to stroke and other types of vascular disease. A simple, non-toxic, and inexpensive intervention in the form of multivitamins (folate, B6 and B12) has been shown to be highly effective at reducing homocysteine levels, irrespective of the underlying cause. All patients who are referred to a neurologist or general physician in one of the collaborating centres within six months of a stroke or transient ischaemic attack are eligible for the trial. In total, treatment will continue for a period of between 1 and 5 years. During this time, patients will be closely monitored in order to record the occurrence of any vascular events (particularly strokes and heart attacks). Neither the study investigator nor the patient will know which treatment they are receiving (i.e. it is 'double blind'). The number of vascular events in the treatment groups will be compared at the end of the study in order to determine whether vitamin treatment is beneficial. This application is for five years of support to allow the investigators to move from the pilot phase of VITATOPS in Perth to begin recruitment to the definitive trial in other centres across Australia and New Zealand. This study may have a major impact on patient management. If vitamins prove to be effective, we may recommend vitamin supplementation to all of our stroke patients in the future.Read moreRead less
A Randomised Placebo-controlled Crossover Trial Of Micronised Resveratrol As A Treatment For Friedreich Ataxia
Funder
National Health and Medical Research Council
Funding Amount
$556,287.00
Summary
Friedreich ataxia (FRDA) is the most common inherited cause of ataxia (incoordination). There are currently no treatments proven to slow or reverse its inexorable progression. We have shown that resveratrol holds promise as a treatment in an open-label study and now propose a placebo controlled study that will provide evidence of whether resveratrol can slow or reverse symptoms in this devastating disorder.